|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.01 USD | +0.34% |
|
-6.94% | +39.06% |
| Jan. 30 | Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating | MT |
| Jan. 30 | Mib Outperforms Europe Ahead of S&P, Campari Leads Gains | AN |
Company Valuation: Moderna, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 41,340 | 102,976 | 69,006 | 37,919 | 16,001 | 16,024 | 16,024 | - |
| Change | - | 149.1% | -32.99% | -45.05% | -57.8% | 0.15% | 0% | - |
| Enterprise Value (EV) 1 | 36,842 | 92,848 | 59,104 | 29,315 | 8,976 | 11,172 | 13,249 | 14,725 |
| Change | - | 152.02% | -36.34% | -50.4% | -69.38% | 24.47% | 18.6% | 11.14% |
| P/E ratio | -53.3x | 8.98x | 8.93x | -8.07x | -4.48x | -5.2x | -6.01x | -8.68x |
| PBR | 16.3x | 7.24x | 3.7x | 2.74x | 1.46x | 1.87x | 2.5x | 3.49x |
| PEG | - | -0x | -0.3x | 0x | 0.2x | 0.3x | 0.4x | 0.3x |
| Capitalization / Revenue | 51.5x | 5.58x | 3.58x | 5.54x | 4.94x | 8.54x | 7.84x | 6.53x |
| EV / Revenue | 45.9x | 5.03x | 3.07x | 4.28x | 2.77x | 5.95x | 6.48x | 6x |
| EV / EBITDA | -50.3x | 6.86x | 6.05x | -8.1x | -2.39x | -3.57x | -4.87x | -8.16x |
| EV / EBIT | -48.3x | 6.98x | 6.27x | -6.92x | -2.28x | -3.39x | -4.62x | -7.36x |
| EV / FCF | 18.8x | 6.96x | 12.9x | -7.66x | -2.21x | -4.26x | -5.49x | -8.75x |
| FCF Yield | 5.32% | 14.4% | 7.75% | -13% | -45.2% | -23.5% | -18.2% | -11.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.96 | 28.29 | 20.12 | -12.33 | -9.28 | -7.889 | -6.825 | -4.727 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 803.4 | 18,471 | 19,263 | 6,848 | 3,236 | 1,877 | 2,045 | 2,453 |
| EBITDA 1 | -731.9 | 13,528 | 9,768 | -3,618 | -3,756 | -3,126 | -2,723 | -1,805 |
| EBIT 1 | -763.1 | 13,296 | 9,420 | -4,239 | -3,945 | -3,296 | -2,870 | -2,001 |
| Net income 1 | -747.1 | 12,202 | 8,362 | -4,714 | -3,561 | -3,024 | -2,657 | -1,871 |
| Net Debt 1 | -4,498 | -10,128 | -9,902 | -8,604 | -7,025 | -4,852 | -2,775 | -1,299 |
| Reference price 2 | 104.47 | 253.98 | 179.62 | 99.45 | 41.58 | 41.01 | 41.01 | 41.01 |
| Nbr of stocks (in thousands) | 395,710 | 405,450 | 384,180 | 381,284 | 384,818 | 390,734 | 390,734 | - |
| Announcement Date | 2/25/21 | 2/24/22 | 2/23/23 | 2/22/24 | 2/14/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.2x | 5.95x | -3.57x | -.--% | 16.02B | |
| 19.89x | 4.62x | 12.7x | 0.5% | 80.61B | |
| 24.12x | 4.35x | 12.65x | 2.44% | 61B | |
| 41.98x | 6.59x | 20.94x | 0.54% | 58.81B | |
| 50.25x | 13.26x | 28.45x | -.--% | 52.77B | |
| 16.66x | 3.28x | 9.56x | -.--% | 29.52B | |
| 17.51x | 3.47x | 10.37x | -.--% | 21.28B | |
| 73.24x | 8.58x | 82.3x | -.--% | 17.65B | |
| 666.07x | 5.19x | 13.27x | -.--% | 15.17B | |
| Average | 100.50x | 6.14x | 20.74x | 0.39% | 39.2B | |
| Weighted average by Cap. | 57.75x | 6.30x | 18.78x | 0.63% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- MRNA Stock
- Valuation Moderna, Inc.
Select your edition
All financial news and data tailored to specific country editions
